Biomarker tests for risk assessment in coronary artery disease

Will they change clinical practice?

Johannes Mair, Allan S Jaffe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The clinical significance and economic impact of coronary artery disease has triggered major research efforts into the discovery of novel biomarkers for risk stratification in primary and secondary prevention and then the development of assays suitable for routine measurement. Nevertheless, the clinical impact of these novel biomarkers for risk stratification is still limited because they do not add substantially to traditional risk factors and they only modestly - even with a multimarker approach - improve risk stratification and patient reclassification. The most useful markers appear to be high-sensitivity C-reactive protein, natriuretic peptides, and, eventually, high-sensitivity cardiac troponins. Further research is clearly needed.

Original languageEnglish (US)
Pages (from-to)5-15
Number of pages11
JournalMolecular Diagnosis and Therapy
Volume18
Issue number1
DOIs
StatePublished - Feb 2014

Fingerprint

Coronary Artery Disease
Biomarkers
Natriuretic Peptides
Troponin
Primary Prevention
Secondary Prevention
Research
C-Reactive Protein
Economics

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Medicine(all)
  • Pharmacology

Cite this

Biomarker tests for risk assessment in coronary artery disease : Will they change clinical practice? / Mair, Johannes; Jaffe, Allan S.

In: Molecular Diagnosis and Therapy, Vol. 18, No. 1, 02.2014, p. 5-15.

Research output: Contribution to journalArticle

@article{f13613bb3d7047709a145591624b6145,
title = "Biomarker tests for risk assessment in coronary artery disease: Will they change clinical practice?",
abstract = "The clinical significance and economic impact of coronary artery disease has triggered major research efforts into the discovery of novel biomarkers for risk stratification in primary and secondary prevention and then the development of assays suitable for routine measurement. Nevertheless, the clinical impact of these novel biomarkers for risk stratification is still limited because they do not add substantially to traditional risk factors and they only modestly - even with a multimarker approach - improve risk stratification and patient reclassification. The most useful markers appear to be high-sensitivity C-reactive protein, natriuretic peptides, and, eventually, high-sensitivity cardiac troponins. Further research is clearly needed.",
author = "Johannes Mair and Jaffe, {Allan S}",
year = "2014",
month = "2",
doi = "10.1007/s40291-013-0057-0",
language = "English (US)",
volume = "18",
pages = "5--15",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Biomarker tests for risk assessment in coronary artery disease

T2 - Will they change clinical practice?

AU - Mair, Johannes

AU - Jaffe, Allan S

PY - 2014/2

Y1 - 2014/2

N2 - The clinical significance and economic impact of coronary artery disease has triggered major research efforts into the discovery of novel biomarkers for risk stratification in primary and secondary prevention and then the development of assays suitable for routine measurement. Nevertheless, the clinical impact of these novel biomarkers for risk stratification is still limited because they do not add substantially to traditional risk factors and they only modestly - even with a multimarker approach - improve risk stratification and patient reclassification. The most useful markers appear to be high-sensitivity C-reactive protein, natriuretic peptides, and, eventually, high-sensitivity cardiac troponins. Further research is clearly needed.

AB - The clinical significance and economic impact of coronary artery disease has triggered major research efforts into the discovery of novel biomarkers for risk stratification in primary and secondary prevention and then the development of assays suitable for routine measurement. Nevertheless, the clinical impact of these novel biomarkers for risk stratification is still limited because they do not add substantially to traditional risk factors and they only modestly - even with a multimarker approach - improve risk stratification and patient reclassification. The most useful markers appear to be high-sensitivity C-reactive protein, natriuretic peptides, and, eventually, high-sensitivity cardiac troponins. Further research is clearly needed.

UR - http://www.scopus.com/inward/record.url?scp=84893323236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893323236&partnerID=8YFLogxK

U2 - 10.1007/s40291-013-0057-0

DO - 10.1007/s40291-013-0057-0

M3 - Article

VL - 18

SP - 5

EP - 15

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 1

ER -